EcoDrugPlus

Egl-9 Family Hypoxia-Inducible Factor 1b

Ensembl ID : ENSDARG00000004632
Gene Symbol: EGLN1B
5 Cross references
174 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 1b

Ensembl ID : ENSDARG00000105156
Gene Symbol: EGLN1B
3 Cross references
174 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSDARG00000062562
Gene Symbol: EGLN2
4 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSDARG00000032553
Gene Symbol: EGLN3
4 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Endothelial Pas Domain Protein 1a

Ensembl ID : ENSDARG00000008697
Gene Symbol: EPAS1A
5 Cross references
153 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSDARG00000057671
Gene Symbol: EPAS1B
8 Enzyme and pathways 5 Cross references
214 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSDARG00000061737
Gene Symbol: ECE1
5 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Endothelin Receptor Ba

Ensembl ID : ENSDARG00000089334
Gene Symbol: EDNRBA
7 Enzyme and pathways 5 Cross references
156 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSDARG00000011876
Gene Symbol: EDNRAA
7 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSDARG00000062262
Gene Symbol: EDNRAB
5 Cross references
201 Possible Orthologues:

Endothelin Receptor Type Bb

Ensembl ID : ENSDARG00000053498
Gene Symbol: EDNRBB
5 Cross references
200 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSDARG00000010571
Gene Symbol: EZH2
15 Enzyme and pathways 5 Cross references
240 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).